Prokidney (PROK) Capital Expenditures (2021 - 2026)

Prokidney (PROK) has reported Capital Expenditures for 6 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 23.17% year-over-year to $3.8 million in Q2 2026; TTM through Jun 2026 was $18.6 million, a 42.27% decrease from a year earlier, with the FY2025 full-year figure at $15.2 million, down 48.5% from the prior year.
• Capital Expenditures was $3.8 million for Q2 2026 at Prokidney, up from $3.8 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $27.9 million in Q3 2023 and troughed at $306000.0 in Q4 2022.
• A 5-year average of $4.9 million and a median of $2.0 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 8769.52% in 2023 and slumped 91.4% in 2024, its largest moves.
• Over 5 years, Capital Expenditures stood at $306000.0 in 2022, then soared by 413.73% to $1.6 million in 2023, then surged by 1522.71% to $25.5 million in 2024, then tumbled by 77.45% to $5.8 million in 2025, then plunged by 33.36% to $3.8 million in 2026.
• The last three Capital Expenditures figures came in at $3.8 million (Q2 2026), $3.8 million (Q1 2026), and $5.8 million (Q4 2025), per Business Quant data.